"Carcinoma, Renal Cell" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma.
| Descriptor ID |
D002292
|
| MeSH Number(s) |
C04.557.470.200.025.390 C04.588.945.947.535.160 C12.758.820.750.160 C12.777.419.473.160 C13.351.937.820.535.160 C13.351.968.419.473.160
|
| Concept/Terms |
Carcinoma, Renal Cell- Carcinoma, Renal Cell
- Carcinomas, Renal Cell
- Renal Cell Carcinomas
- Adenocarcinoma, Renal Cell
- Adenocarcinomas, Renal Cell
- Renal Cell Adenocarcinoma
- Renal Cell Adenocarcinomas
- Adenocarcinoma Of Kidney
- Adenocarcinoma Of Kidneys
- Kidney, Adenocarcinoma Of
- Kidneys, Adenocarcinoma Of
- Renal Cell Cancer
- Cancer, Renal Cell
- Cancers, Renal Cell
- Renal Cell Cancers
- Adenocarcinoma, Renal
- Adenocarcinomas, Renal
- Renal Adenocarcinoma
- Renal Adenocarcinomas
- Nephroid Carcinoma
- Carcinoma, Nephroid
- Carcinomas, Nephroid
- Nephroid Carcinomas
- Renal Cell Carcinoma
Clear Cell Renal Cell Carcinoma- Clear Cell Renal Cell Carcinoma
- Grawitz Tumor
- Tumor, Grawitz
- Clear Cell Renal Carcinoma
- Carcinoma, Hypernephroid
- Carcinomas, Hypernephroid
- Hypernephroid Carcinoma
- Hypernephroid Carcinomas
- Hypernephroma
- Hypernephromas
Collecting Duct Carcinoma (Kidney)- Collecting Duct Carcinoma (Kidney)
- Carcinoma, Collecting Duct (Kidney)
- Carcinomas, Collecting Duct (Kidney)
- Collecting Duct Carcinomas (Kidney)
- Collecting Duct Carcinoma of the Kidney
- Renal Collecting Duct Carcinoma
- Collecting Duct Carcinoma
- Carcinoma, Collecting Duct
- Carcinomas, Collecting Duct
- Collecting Duct Carcinomas
|
Below are MeSH descriptors whose meaning is more general than "Carcinoma, Renal Cell".
Below are MeSH descriptors whose meaning is more specific than "Carcinoma, Renal Cell".
This graph shows the total number of publications written about "Carcinoma, Renal Cell" by people in this website by year, and whether "Carcinoma, Renal Cell" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1996 | 2 | 0 | 2 |
| 1997 | 2 | 0 | 2 |
| 1998 | 2 | 0 | 2 |
| 1999 | 1 | 0 | 1 |
| 2000 | 2 | 1 | 3 |
| 2001 | 4 | 0 | 4 |
| 2002 | 7 | 3 | 10 |
| 2003 | 7 | 1 | 8 |
| 2004 | 8 | 0 | 8 |
| 2005 | 4 | 0 | 4 |
| 2006 | 6 | 0 | 6 |
| 2007 | 5 | 0 | 5 |
| 2008 | 6 | 1 | 7 |
| 2009 | 9 | 0 | 9 |
| 2010 | 4 | 1 | 5 |
| 2011 | 4 | 0 | 4 |
| 2012 | 4 | 0 | 4 |
| 2013 | 6 | 0 | 6 |
| 2014 | 11 | 4 | 15 |
| 2015 | 12 | 0 | 12 |
| 2016 | 12 | 0 | 12 |
| 2017 | 9 | 0 | 9 |
| 2018 | 10 | 0 | 10 |
| 2019 | 4 | 0 | 4 |
| 2020 | 10 | 1 | 11 |
| 2021 | 8 | 0 | 8 |
| 2022 | 3 | 1 | 4 |
| 2023 | 8 | 0 | 8 |
| 2024 | 9 | 1 | 10 |
| 2025 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Carcinoma, Renal Cell" by people in Profiles.
-
CA-125 as a Biomarker in Renal Medullary Carcinoma: Integrated Molecular Profiling, Functional Characterization, and Prospective Clinical Validation. Clin Cancer Res. 2025 Mar 17; 31(6):1057-1068.
-
Sitravatinib in combination with nivolumab plus ipilimumab in patients with advanced clear cell renal cell carcinoma: a phase 1 trial. Nat Commun. 2025 Jan 10; 16(1):578.
-
Targeting Siglec-E facilitates tumor vaccine-induced antitumor immunity in renal carcinoma. J Immunother Cancer. 2025 Jan 04; 13(1).
-
Prognostic significance of body mass index in patients with metastatic renal cell carcinoma receiving first-line therapies. Urol Oncol. 2025 04; 43(4):269.e1-269.e6.
-
Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis of Individual Patient Data. Eur Urol Focus. 2025 Mar; 11(2):356-364.
-
Impact of postprogression therapies on overall survival: Recommendations from the 2023 kidney cancer association think tank meeting. Urol Oncol. 2025 03; 43(3):135-146.
-
Antiangiogenic Tyrosine Kinase Inhibitors have Differential Efficacy in Clear Cell Renal Cell Carcinoma in Bone. Cancer Res Commun. 2024 10 01; 4(10):2621-2637.
-
Belzutifan Efficacy and Tolerability in Patients with Sporadic Metastatic Clear Cell Renal Cell Carcinoma. Eur Urol Focus. 2025 Jan; 11(1):150-158.
-
Upfront Versus Deferred Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma: A Systematic Review and Individual Patient Data Meta-analysis. Eur Urol Focus. 2025 Jan; 11(1):100-108.
-
Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell Carcinoma. J Clin Oncol. 2024 Nov 20; 42(33):3911-3916.